ANI Pharmaceuticals (NASDAQ:ANIP) Hits New 12-Month Low – Should You Sell?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) reached a new 52-week low during trading on Thursday. The company traded as low as $69.39 and last traded at $69.6420, with a volume of 919,002 shares trading hands. The stock had previously closed at $71.65.

Trending Headlines about ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI reported Q3 2026 adjusted earnings of $2.70 per share, above the roughly $2.18 analyst consensus, and revenue of $290.78 million versus estimates of $280.59 million. Revenue grew 27.6% year over year, supporting the company’s growth outlook. ANI Q3 financial results
• Positive Sentiment: Guggenheim raised its price target from $119 to $121 and maintained a Buy rating, signaling continued analyst confidence in ANIP’s prospects. Guggenheim ratings
• Neutral Sentiment: ANI announced a recommended offer to acquire Swedish biotech Egetis Therapeutics for SEK 5.6 billion (about $560 million). The deal would expand ANI’s rare-disease business, but its financial impact and execution will matter to investors. ANI offer for Egetis
• Negative Sentiment: The sizable acquisition may raise concerns about funding, integration, and the risks of expanding into a new business, potentially weighing on shares despite the earnings beat. ANI offer to acquire Egetis

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Guggenheim upped their price target on ANI Pharmaceuticals from $119.00 to $121.00 and gave the company a “buy” rating in a report on Friday. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Oppenheimer initiated coverage on ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 target price for the company. Canaccord Genuity Group reduced their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Finally, Leerink Partners began coverage on ANI Pharmaceuticals in a research report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 price target on the stock. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $100.00.

ANI Pharmaceuticals Stock Down 3.2%

The stock has a market capitalization of $1.55 billion, a PE ratio of 13.43, a P/E/G ratio of 2.28 and a beta of 0.45. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The stock’s fifty day simple moving average is $72.52 and its 200-day simple moving average is $77.32.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.18 by $0.52. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The firm had revenue of $290.78 million during the quarter, compared to analyst estimates of $280.59 million. During the same period last year, the company earned $2.04 earnings per share. The business’s revenue for the quarter was up 27.6% on a year-over-year basis. As a group, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 7.76 EPS for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, Director Jeanne Thoma sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $71.53, for a total transaction of $71,530.00. Following the sale, the director directly owned 26,762 shares in the company, valued at $1,914,285.86. This represents a 3.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen Carey sold 2,850 shares of the company’s stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $72.87, for a total value of $207,679.50. Following the completion of the sale, the chief financial officer owned 166,143 shares of the company’s stock, valued at $12,106,840.41. This represents a 1.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 30,412 shares of company stock worth $2,220,970 over the last three months. 8.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ANIP. Aberdeen Group plc raised its position in ANI Pharmaceuticals by 23.0% in the third quarter. Aberdeen Group plc now owns 334,350 shares of the specialty pharmaceutical company’s stock worth $24,291,000 after acquiring an additional 62,590 shares in the last quarter. Eurizon Capital SGR S.p.A. acquired a new position in ANI Pharmaceuticals during the 3rd quarter valued at about $32,000. Maryland State Retirement & Pension System grew its holdings in shares of ANI Pharmaceuticals by 66.4% during the 3rd quarter. Maryland State Retirement & Pension System now owns 4,430 shares of the specialty pharmaceutical company’s stock valued at $322,000 after acquiring an additional 1,768 shares in the last quarter. Illinois Municipal Retirement Fund lifted its stake in shares of ANI Pharmaceuticals by 7.2% in the third quarter. Illinois Municipal Retirement Fund now owns 9,719 shares of the specialty pharmaceutical company’s stock valued at $706,000 after buying an additional 651 shares during the period. Finally, Penn Capital Management Company LLC lifted its holdings in ANI Pharmaceuticals by 2.8% during the 3rd quarter. Penn Capital Management Company LLC now owns 213,246 shares of the specialty pharmaceutical company’s stock worth $15,515,000 after buying an additional 5,884 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.